Arbele Limited
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Novel T-cell engager, CDH17 X CD3 cabotamig (ARB202) continues to explore dosing in patients with advanced gastrointestinal cancers 2024-04-26 21:00
Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting 2023-08-03 07:00
Arbele celebrates its 7th anniversary as a clinical-stage immunotherapy biotech and the opening of TibTech, its cancer diagnostics subsidiary 2023-05-05 15:00
Arbele Announces Phase 1 First-in-Human Study of CDH17xCD3 Bispecific T-Cell Engager for Treatment of Gastrointestinal Cancers 2022-08-10 20:00
1